



AJOONI BIOTECH LIMITED

Regd. Office: D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.)

Corp Office: H.No 1769, Phase 3B2, Mohali-160059

Phone: 0172-5020758-69 Website: www.ajoonibiotech.com

E-mail: ajooni.biotech@gmail.com / info@ajoonibiotech.com

CIN: L85190PB2010PLC040162

June 29, 2026

To,

National Stock Exchange of India Ltd,

Exchange Plaza, 5th Floor, Plot No. C/1, G Block,

Bandra Kurla Complex, Bandra (East), Mumbai – 400 051

Company Symbol: AJOONI, ISIN: INE820Y01021

Sub: Outcome of Board Meeting under Regulation 30 of the SEBI (LODR) Regulations, 2015.

Dear Sir/ Madam,

With reference to the subject cited, this is to inform the Exchange that the meeting of the Board of Directors of Ajooni Biotech Limited held on Monday, June 29, 2026 at the Corporate office of the Company, the following were considered and approved:

1. The Board of Directors of the Company has decided to increase the Authorized Share Capital from Rs. 50,00,00,000 (Rupees Fifty Crores Only) divided into 25,00,00,000 (Twenty Five Crores) Equity Shares of Rs. 2/- (Rupees Two Only) each to Rs. 70,00,00,000/- (Rupees Seventy Crores Only) divided into 35,00,00,000 (Thirty Five Crores) Equity Shares of having face value of Rs. 2/- (Rupees Two Only) ranking pari passu with the existing Equity Shares of the Company.
2. Issue, offer and allot upto 90,00,000 Equity Shares on preferential basis to the persons belonging to the Promoter at such price as determined in accordance with the provision of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 as amended from time to time, subject to the approval of shareholders of the Company.

Further the necessary details with respect to point no. 1 are disclosed in Annexure-A and for point no. 2 are disclosed in Annexure-B as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 November 11, 2024 and SEBI Master Circular dated January 30, 2026.

3. The Board decided to defer the proposal for revision/partial modification of the terms and conditions of remuneration of Mr. Jasjot Singh, Managing Director, for consideration at a subsequent Board Meeting to enable further review of the proposal. Until such time, the existing terms and conditions of his remuneration shall continue to remain in effect.
4. Appointment of M/s. M.R. Chechi & Associates, Practicing Company Secretaries, Chandigarh as Scrutinizer to scrutinize the e-voting process in fair and transparent manner of AGM;
5. Book-closure dates from July 23, 2026 to July 29, 2026 (both days inclusive) for the purpose of 16th AGM as per regulation 42 of the SEBI (LODR) Regulations, 2015. Accordingly, the cut off date, to ascertain the eligibility of members for remote e-voting and polling at AGM, is Friday, July 17, 2026 i.e. the date prior to the commencement of book closure.
6. Draft director's report for the F.Y. 2025-26 for the purpose of 16th Annual General Meeting.



AJOONI BIOTECH LIMITED

Regd. Office: D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.)

Corp Office: H.No 1769, Phase 3B2, Mohali-160059

Phone: 0172-5020758-69 Website: www.ajoonibiotech.com

E-mail: ajooni.biotech@gmail.com / info@ajoonibiotech.com

CIN: L85190PB2010PLC040162

7. Approved convening of Annual General Meeting ('AGM') of the members of the Company on Wednesday, July 29, 2026 through Video Conferencing ('VC')/ Other Audio-Visual Means ('OAVM') as per the relevant circulars of MCA and SEBI for obtaining the shareholders' approval for the above mentioned items. The AGM notice shall be submitted to stock exchange when it will be circulated to members of the Company as per the applicable provision of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015;

The meeting of the Board of Directors commenced at 02.00 pm and concluded at 03.15 pm.

Kindly arrange to take the same on your records.

For Ajooni Biotech Limited

Jasjot Singh
Managing Director
DIN: 01937631



AJOONI BIOTECH LIMITED

Regd. Office: D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.)

Corp Office: H.No 1769, Phase 3B2, Mohali-160059

Phone: 0172-5020758-69 Website: www.ajoonibiotech.com

E-mail: ajooni.biotech@gmail.com / info@ajoonibiotech.com

CIN: L85190PB2010PLC040162

Annexure - A

Disclosure of Information pursuant to Regulation 30 of the SEBI Listing Regulations read with SEBI circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 November 11, 2024 and SEBI Master Circular dated January 30, 2026.

Brief Details of amendment to Memorandum of Association

Amendment to the Authorized Share Capital in Clause V of the Memorandum of Association of the Company.

V. *The Authorised Share Capital of the Company is Rs. 70,00,00,000/- (Rupees Seventy Crores Only) divided into 35,00,00,000 (Thirty Five Crores) Equity Shares of having face value of Rs. 2/- (Rupees Two Only) each.*



AJOONI BIOTECH LIMITED

Regd. Office: D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.)

Corp Office: H.No 1769, Phase 3B2, Mohali-160059

Phone: 0172-5020758-69 Website: www.ajoonibiotech.com

E-mail: ajooni.biotech@gmail.com / info@ajoonibiotech.com

CIN: L85190PB2010PLC040162

Annexure - B

Disclosure of Information pursuant to Regulation 30 of the SEBI Listing Regulations read with SEBI circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 November 11, 2024 and SEBI Master Circular dated January 30, 2026.

Sl. No.	Particulars	Details
1	Type of securities proposed to be issued	Equity Shares
2	Type of issuance	Preferential issue in terms of Section 42 read with Section 62 of the Companies Act, 2013 and other applicable provisions and SEBI ICDR Regulations.
3	Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately);	90,00,000 Equity Shares on preferential basis to the Promoter. The issue price is Rs. 4.30/- per equity share calculated in accordance with SEBI ICDR Regulations.
4	Total amount for which the securities will be Issued	Aggregating to Rs. 3,87,00,000/- for issue 90,00,000 Equity Shares at issue price of Rs. 4.30/- each to the persons belonging to Promoters.
In case of preferential issue, the listed entity shall disclose the following additional details to the stock exchange(s)		
5	Name of Investors	Healthy Biosciences Limited
6	Post allotment of securities - outcome of the subscription, issue price / allotted price (in case of convertibles), number of investors. In case of convertibles - intimation conversion of securities or on lapse of the tenure	Issue, offer and allot upto 90,00,000 Equity Shares at a price of Rs. 4.30/-. The issue price is not lower than the floor price determined in accordance with the Regulation 164(1) of Chapter V of SEBI ICDR Regulations. The issuance of Equity Shares is subject to the approval of members by way of passing special resolution at the Annual General Meeting to be held on July 29, 2026.
7	Any cancellation or termination of proposal for issuance of securities including reasons thereof	Not Applicable

Name / List of Investors:

Sr. No.	Name of the Proposed Allottees	Pre-Preferential holding	Pre %	No. of Equity Shares to be issued	Post-Preferential Holding	Post %	Category
1.	Healthy Biosciences Limited	0	0.00	90,00,000	90,00,000	4.97	Promoter
	Total	0	0.00	90,00,000	90,00,000	4.97	

Pre and Post Shareholding:

Category	Pre preferential issue		Post preferential issue	
	No of Shares	%	No of Shares	%
Promoters and Promoter Group (A)	4,63,24,766	26.89	5,53,24,766	30.53
Public (B)	12,59,18,832	73.11	12,59,18,832	69.47
Total (A) + (B)	17,22,43,598	100.00	18,12,43,598	100.00
Custodian (C)	0	0.00	0	0.00
Grand Total (A) + (B) + (C)	17,22,43,598	100.00	18,12,43,598	100.00